Infertility and Reproductive Health Research Center, IVF Department, Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Oncology Department, Radio-oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clin Breast Cancer. 2018 Oct;18(5):395-399. doi: 10.1016/j.clbc.2018.03.003. Epub 2018 Mar 15.
This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer.
This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Beheshti University of Medical Sciences between 2011 and 2013. Data were collected via in-person interviews using a questionnaire, which included demographic and gynecologic information. Statistical analysis was performed using SPSS statistics software version 20 (IBM Corp).
The use of ovulation induction drugs was not significantly associated with an increased risk of breast cancer (odds ratio [OR], 1.13; 95% confidence interval [CI], 0.7-1.855) among women with infertility (OR, 1.28; 95% CI, 0.8-1.95).
We observed no statistically significant relationship between infertility and ovulation induction drugs with the risk of breast cancer, except for significant increases in the risk of breast cancer among patients who had used fertility drugs for >6 months.
本研究旨在确定在治疗不孕症中使用排卵诱导药物是否会显著增加乳腺癌的风险。
这是一项病例对照研究（928 例病例，928 例对照），于 2011 年至 2013 年在沙希德贝赫什提大学医学科学的妇科和肿瘤科进行。通过使用问卷进行面对面访谈收集数据，问卷包括人口统计学和妇科信息。使用 SPSS 统计软件版本 20（IBM Corp）进行统计分析。
在不孕症女性中，使用排卵诱导药物与乳腺癌风险增加之间无显著相关性（比值比 [OR]，1.13；95%置信区间 [CI]，0.7-1.855）（OR，1.28；95%CI，0.8-1.95）。
除了使用生育药物 >6 个月的患者乳腺癌风险显著增加外，我们未观察到不孕症与排卵诱导药物与乳腺癌风险之间存在统计学显著关系。
